MOTS-cMitochondrial-derived signalling peptide
MOTS-c is a small mitochondrial-derived peptide studied in metabolic signalling. Findings about the body’s own peptide and animal experiments are intriguing, but they do not establish the benefits of administering it to people.
What is MOTS-c?
MOTS-c is a mitochondrially encoded signalling peptide investigated in metabolic-stress biology. Research on the body’s own peptide and research on administering a manufactured peptide are different evidence categories.
How it works
It is studied as part of communication between mitochondrial activity and broader cellular metabolic responses. A role in stress signalling does not establish that supplementation reproduces exercise.
Effects studied
The human finding was about exercise
In a 2021 study, 10 healthy young men completed a cycling session. Their naturally produced MOTS-c increased in muscle and blood around exercise. This shows that the peptide responds to exercise in that small group. The participants were not receiving MOTS-c injections, so this part of the study cannot establish a treatment benefit. 1
Evidence: Small human exercise observation; endogenous peptide measured.
The mouse experiment tested administration
In the same paper, administered MOTS-c improved running performance in mice across several ages. This is a positive intervention finding and a reason to explore physical-function effects further. It does not mean every function improved: the reported tests did not show better grip strength or Barnes-maze performance. Whether a defined MOTS-c product improves human endurance or metabolic health remains unresolved by these results. 1
Evidence: Animal intervention; no demonstrated human treatment effect from this study.
What does the evidence show?
Human exercise observations and mouse interventions
A signal with a mitochondrial origin
MOTS-c is described as a peptide encoded within mitochondrial genetic material. Researchers are exploring its role in communication between metabolic stress and cellular responses. This work concerns a biological signalling system; it does not establish that taking the peptide supplies extra energy.
The human finding was about exercise
In a 2021 study, 10 healthy young men completed a cycling session. Their naturally produced MOTS-c increased in muscle and blood around exercise. This shows that the peptide responds to exercise in that small group. The participants were not receiving MOTS-c injections, so this part of the study cannot establish a treatment benefit. 1
The mouse experiment tested administration
In the same paper, administered MOTS-c improved running performance in mice across several ages. This is a positive intervention finding and a reason to explore physical-function effects further. It does not mean every function improved: the reported tests did not show better grip strength or Barnes-maze performance. Whether a defined MOTS-c product improves human endurance or metabolic health remains unresolved by these results. 1
The treatment question remains separate
A defined MOTS-c product would need evidence on human pharmacology, meaningful clinical outcomes and longer-term safety. Immune responses, impurities and manufacturing consistency also need investigation. A naturally occurring sequence cannot be assumed harmless when administered. The biology offers reasons for research, but does not yet support performance or longevity promises.
Safety & status
Human pharmacology and longer-term safety remain insufficiently characterised. Purity, immune responses and the difference between a natural signal and an administered product are relevant uncertainties.
FDA’s 2026 assessment highlights limited human safety evidence and potential immune-reaction and impurity concerns. 2
Country and product status
Country-specific product availability and authorisation require a separate current check.
Frequently asked questions
Is an exercise-related increase evidence that injections work?
No. An association with exercise does not show that administering the peptide produces exercise’s benefits.
Are human longevity benefits established?
No. The retained evidence does not establish that outcome.
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Reynolds et al. (2021): MOTS-c enhances physical performance in mice and is induced by exercise in humans Primary animal intervention and human exercise study · Primary-paper results and figure captions checked; checked 2026-10-29
- FDA (2026): MOTS-c compounding advisory assessment Regulatory evidence review · Relevant evidence/safety assessment excerpt checked; advisory assessment is not approval; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.